CRUSH ReportsCRUSH Alerts 2.0CRUSH Industry ReportsCRUSHarmyContact Manager ApplicationMid-Market Manager ApplicationTarget Builder Application
 

Quest Diagnostics (DGX)

The Quest Diagnostics CRUSH Report is a Fortune 1000 deep dive sales intelligence company profile and will help increase your sales leads and add more accounts in your sales pipeline while eliminating costly research time.

The Quest Diagnostics CRUSH Report contains insights to IT architectures, business and technology initiatives, corporate strategies, projects and budgets, org charts and key decision-maker contact info.

The Quest Diagnostics CRUSH Report allows IT sales and marketing professionals to:
  • Jump-start sales cycles in net new accounts
  • Expand footprints in existing customer accounts
  • Facilitate the strategic account planning process
  • Respond to RFPs & bids more effectively
  • Build better content into executive level presentations
  • Identify the presence of competitors & partners
The Quest Diagnostics CRUSH Report has the competitive intelligence needed for account planning within the Fortune 1000. Target the right people, with the right message at the right time using our org charts, decision maker contact info, business drivers and IT landscapes.

Click here to download free sample CRUSH Reports

Quest Diagnostics News Release

A Collection of Quest Diagnostics News Release

Quest Diagnostics Extends Endocrine Diagnostic Menu with New Congenital Adrenal Hyperplasia (CAH) Steroid Screening Panels
Thursday May 17th 2012 03:28:48 PM

Features newborn screening panel that measures all 13 CAH-associated steroids by tandem mass spectrometry in a single analysis MADISON, N.J., May 17, 2012 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, has extended its endocrine diagnostics menu with the introduction of four new tests panels for congenital adrenal hyperplasia (CAH), an endocrine disorder found in newborns, children and women. The panels are designed to overcome limitations in conventional testing to provide faster, high quality diagnosis of CAH in a single analysis. "CAH is challenging to diagnose, and often escapes fast de...

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Quest Diagnostics Reminds Women to Make Their Health a Priority During National Women's Health Week
Wednesday May 16th 2012 08:00:10 AM

Company Distributes 10,000 Vouchers for Free Wellness Screenings in May in Support of American Cancer Society Choose You® Women's Health Movement MADISON, N.J., May 16, 2012 /PRNewswire/ -- This week, National Women's Health Week, Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, joins the American Cancer Society Choose You® movement and the U.S. Department of Health and Human Services' (HHS) Office on Women's Health (OWH) in reminding women to make their health a priority. National Women's Health Week is a weeklong health observance coordinated by the U.S. Department of Health and Human Services' Office on Women's Health. It br...

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Quest Diagnostics Declares Quarterly Cash Dividend
Friday May 11th 2012 02:18:58 PM

MADISON, N.J., May 11, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend of $0.17 per share, payable on July 18, 2012, to shareholders of record of Quest Diagnostics common stock on July 3, 2012. About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service cente...

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Quest Diagnostics Sponsors American Cancer Society Choose You® Women's Health Movement
Tuesday May 1st 2012 05:22:37 PM

Company Offers 10,000 Vouchers for Free Wellness Screenings as National Presenting Sponsor NEW YORK, May 1, 2012 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced its national presenting sponsorship of the American Cancer Society Choose You® movement, which encourages women nationwide to live well today and stay well tomorrow. In support of the Choose You movement and in recognition of National Women's Health Week May 13 – 19 sponsored by the U.S. Department of Health and Human Services Office on Women's Health, Quest Diagnostics will offer 10,000 vouchers for free screenings to women at May Choos...

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Three in Five Americans Misuse Their Prescription Drugs, Finds National Study of Prescription Medication Lab Testing
Friday April 27th 2012 03:09:18 PM

Quest Diagnostics Health Trends(TM) analysis finds many women and men of all ages, income levels and health plan coverage use pain and other prescription medications contrary to clinician orders, potentially putting their health at risk MADISON, N.J., April 27, 2012 /PRNewswire via COMTEX/ --Results of a national study of nearly 76,000 laboratory tests for monitoring prescription drug use indicate that the majority of Americans tested misused their prescription drugs, including potentially addictive pain medications. The results show that more than three in five patients, or 63%, tested through Quest Diagnostics (NYSE: DGX) were inconsistent with clinician orders. The findings suggest man...

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Quest Diagnostics Establishes Unique Healthcare Identifier to Improve Access to Vital Patient Health Information; 80 Million Patient IDs Created to Date
Friday April 27th 2012 03:07:18 PM

MADISON, N.J., April 27, 2012 /PRNewswire via COMTEX/ --Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced it has begun an effort to assign a unique Patient Identifier - a secure 16 digit identification number - to every Quest Diagnostics patient. In what is believed to be the largest effort of its kind in the area of assigning health IDs, the company has assigned unique identifiers to approximately 80 million Quest Diagnostics patients to date. Surya N. Mohapatra, PhD, Chairman and Chief Executive Officer, Quest Diagnostics, called on the healthcare industry to support the adoption of unique Patient IDs to speed and str...

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Quest Diagnostics Announces C9orf72 Genetic Test for ALS (Lou Gehrig's Disease)
Wednesday April 25th 2012 01:41:14 PM

The company's Athena Diagnostics business unit to unveil the new test at the American Academy of Neurology Annual Meeting this week in New Orleans MADISON, N.J. and WORCESTER, Mass., April 25, 2012 /PRNewswire via COMTEX/ --Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced a new genetic testing service from its Athena Diagnostics business unit, a leader in neurology diagnostics, for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. It is the first clinically available testing service for detecting hexanucleotide repeat expansion in the C9orf72 gene. Research published in the April 2012 iss...

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Quest Diagnostics Reports First Quarter 2012 Financial Results
Wednesday April 18th 2012 07:03:27 AM

-- Revenues of $1.9 billion, up 6.3% -- Adjusted diluted EPS of $1.07, up 7.0% -- Reported diluted EPS of $0.99 in 2012 compared to a loss of $0.33 per diluted share in 2011 -- Full year adjusted earnings outlook increased to $4.45 - $4.60 per diluted share MADISON, N.J., April 18, 2012 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that for the first quarter ended March 31, 2012, adjusted income from continuing operations was $171 million, or $1.07 per diluted share, compared to $164 million, or $1.00 per diluted share, in 2011. For the first quarter of 2012, reported ...

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Quest Diagnostics Names Steve Rusckowski as President and CEO
Wednesday April 11th 2012 04:19:39 PM

-- Daniel C. Stanzione, Ph.D. is appointed Non-Executive Chairman of the Board of Directors -- MADISON, N.J., April 11, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX) today announced that Stephen H. Rusckowski will succeed Surya N. Mohapatra, Ph.D. as President and Chief Executive Officer, effective May 1, 2012. Dr. Mohapatra will remain in his role through April 30 to ensure a smooth leadership transition. Mr. Rusckowski will also become a member of the Board of Directors.  (Photo: http://photos.prnewswire.com/prnh/20120411/NY85952 ) The company also announced that Daniel C. Stanzione, Ph.D., currently Lead Independent Director, will become Non-Executive Chairma...

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

FDA Clears the Quest Diagnostics Simplexa® C. difficile Molecular Test
Wednesday April 11th 2012 12:11:19 PM

Test eliminates nucleic-acid sample extraction, for faster results MADISON, N.J. and CYPRESS, Calif., April 11, 2012 /PRNewswire/ -- Quest Diagnostics  (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to its Simplexa C. difficile Universal Direct Test on the 3M™ Integrated Cycler.  The test, from the company's Focus Diagnostics business, is intended to aid in the diagnosis of Clostridium difficile-associated disease, one of the most common and dangerous acquired infections in healthcare settings. It uses a proprietary technique to eliminate the time...

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Decision Chain
Org Charts


Org Chart

Insights to Initiatives, Projects, & Budgets

Decision Maker Contact Info

Contact Info